Status:
COMPLETED
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
Lead Sponsor:
Akeso
Collaborating Sponsors:
AD Pharmaceuticals Co., Ltd.
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardi...
Eligibility Criteria
Inclusion
- Voluntarily sign the informed consent form (ICF), and be able to comply with the treatment plan, visit, laboratory examination and other requirements specified in the study;
- Age ≥ 18, male or female;
- According to the guidelines for the prevention and treatment of dyslipidemia in Chinese adults (revised in 2016), subjects assessed as very high risk or high risk of cardiovascular disease;
- Subjects received stable and optimal dose of statins for at least 4 weeks before randomization, either in combination with or without ezetimibe;
- The blood lipid level of the patients with stable 4-week basic lipid-lowering drug treatment met one of the following conditions by the central laboratory test: LDL-C level in very high risk subjects \> 1.8 mmol / L (70 mg / dl) or LDL-C level of high-risk subjects \> 2.6 mmol / L (100 mg / dl)
- TG ≤ 4.5 mmol / L (400 mg / dl) measured by central laboratory at screening；
Exclusion
- Has received cholesterol ester transfer protein (CETP) inhibitor within12 months prior to randomization;
- Has received PCSK9 inhibitors or are known to be allergic to PCSK9 inhibitors or their components;
- Has received other investigational drugs within 4 weeks or within 5 half lives (whichever was longer) prior to screening.
- Has previously received biological agent treatment, organ transplantation or gene therapy;
- Abnormal laboratories prior to the first study drug administration: ALT or AST\> 3 × ULN; Creatine kinase \> 5 × ULN; eGFR \<= 30 ml/min/1.73m2 by Cockcroft Gault method;
- Uncontrolled hypothyroidism or hyperthyroidism defined as TSH \< 1.0 ×LLN or \> 1.5 × ULN, respectively;
- Myocardial infarction, unstable angina pectoris, percutaneous coronary intervention (PCI), coronary bypass grafting (CABG), stroke, severe deep vein thrombosis or pulmonary embolism, or severe arrhythmia occurred within three months prior to randomization ;
- Grade III or IV according to NYHA assessment;
- Planned to have heart-related surgery within 3 months after randomization;
- Type 1 diabetes or poorly controlled type 2 diabetes \[HbA1c \> 8.5% within 1 month\];
- Subjects with hypertension that could not be controlled by drugs;
- Known concomitant diseases that may lead to secondary hyperlipidemia, including nephrotic syndrome, cholestatic liver failure, etc;
- Positive HBsAg or HCV antibody;
- Known history of primary immunodeficiency virus infection or positive human immunodeficiency virus (HIV) test;
- History of drug or alcohol abuse prior to screening;
- Has taken the following drugs within 6 weeks prior to screening: red koji rice \> 200 mg/day; niacin \> 1000 mg/day; omega-3 fatty acids; steroids or prescription lipid regulating drugs ; cholesterol lowering drugs, health care products, Chinese patent medicines or other food additives other than statins and ezetimibe;
- Has taken the following drugs within 3 months prior to screening: systemic cyclosporine, systemic steroids, vitamin A derivatives and retinol derivatives for the treatment of skin diseases (such as retinoic acid).
Key Trial Info
Start Date :
May 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 25 2021
Estimated Enrollment :
262 Patients enrolled
Trial Details
Trial ID
NCT04358432
Start Date
May 13 2020
End Date
February 25 2021
Last Update
March 2 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhong Shan Hosipital Fu Dan University
Shanghai, China, 200032
2
Affiliated hospital of Guangdong medical university
Zhanjiang, China, 524000